{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:15:46Z","timestamp":1791814546487,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xops.2026.101275","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:45:59Z","timestamp":1780897559000},"page":"101275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Choroidal Changes after Intravitreal Aflibercept, Faricimab, Brolucizumab, and High-Dose Aflibercept in Treatment-Na\u00efve Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"6","author":[{"given":"Sam","family":"Razavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Menna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6214-6270","authenticated-orcid":false,"given":"Serena","family":"Fragiotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Van Herreweghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lazzerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-6177","authenticated-orcid":false,"given":"Marco","family":"Battista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8119-9302","authenticated-orcid":false,"given":"Federico","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Sacconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-9581","authenticated-orcid":false,"given":"Giuseppe","family":"Querques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10153","key":"10.1016\/j.xops.2026.101275_bib1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.xops.2026.101275_bib2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.xops.2026.101275_bib3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5483\/BMBRep.2008.41.4.278","article-title":"Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis","volume":"41","author":"Shibuya","year":"2008","journal-title":"BMB Rep"},{"key":"10.1016\/j.xops.2026.101275_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/bs.ctdb.2016.10.001","article-title":"VEGF receptor tyrosine kinases: key regulators of vascular function","volume":"123","author":"Alvarez-Aznar","year":"2017","journal-title":"Curr Top Dev Biol"},{"issue":"14","key":"10.1016\/j.xops.2026.101275_bib5","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.xops.2026.101275_bib6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.xops.2026.101275_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084433","article-title":"Exploring Current molecular targets in the treatment of neovascular age-related macular degeneration toward the perspective of long-term agents","volume":"25","author":"Fragiotta","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.xops.2026.101275_bib8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.xops.2026.101275_bib9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"44","key":"10.1016\/j.xops.2026.101275_bib10","doi-asserted-by":"crossref","first-page":"18751","DOI":"10.1073\/pnas.0905010106","article-title":"An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris","volume":"106","author":"Saint-Geniez","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.xops.2026.101275_bib11","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1167\/iovs.05-1229","article-title":"VEGF expression and receptor activation in the choroid during development and in the adult","volume":"47","author":"Saint-Geniez","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101275_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100954","article-title":"VEGFR1 signaling in retinal angiogenesis and microinflammation","volume":"84","author":"Uemura","year":"2021","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"10.1016\/j.xops.2026.101275_bib13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ajo.2014.12.025","article-title":"Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration","volume":"159","author":"Koizumi","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.xops.2026.101275_bib14","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00417-015-3260-3","article-title":"Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration","volume":"254","author":"Yun","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.xops.2026.101275_bib15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ajo.2015.08.009","article-title":"Assessment of choroidal topographic changes by swept-source optical coherence tomography after intravitreal ranibizumab for exudative age-related macular degeneration","volume":"160","author":"Razavi","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101275_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/biom12111629","article-title":"Current and novel therapeutic approaches for treatment of neovascular age-related macular degeneration","volume":"12","author":"ElSheikh","year":"2022","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.xops.2026.101275_bib17","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/s41433-020-01309-9","article-title":"Longer-acting treatments for neovascular age-related macular degeneration-present and future","volume":"35","author":"Iglicki","year":"2021","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.xops.2026.101275_bib18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1159\/000527815","article-title":"Factors that can prolong ocular treatment duration in age-related macular degeneration","volume":"66","author":"Kaiser","year":"2023","journal-title":"Ophthalmic Res"},{"issue":"4","key":"10.1016\/j.xops.2026.101275_bib19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","article-title":"Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.xops.2026.101275_bib20","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related Macular Degeneration Nomenclature Study Group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.xops.2026.101275_bib21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12886-025-04257-8","article-title":"Repeatability, reproducibility, and agreement for three optical coherence tomography instruments","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Ophthalmol"},{"issue":"12","key":"10.1016\/j.xops.2026.101275_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1167\/tvst.10.12.26","article-title":"Choroidal vascularity index in different cohorts of dry age-related macular degeneration","volume":"10","author":"Sacconi","year":"2021","journal-title":"Transl Vis Sci Technol"},{"issue":"2","key":"10.1016\/j.xops.2026.101275_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/IAE.0000000000003305","article-title":"Choroidal vascularity index is associated with geographic atrophy progression","volume":"42","author":"Sacconi","year":"2022","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.xops.2026.101275_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.survophthal.2024.09.011","article-title":"Choroidal thickness after anti-vascular endothelial growth factor in typical neovascular age-related macular degeneration - a systematic review and meta-analysis","volume":"70","author":"Hoven","year":"2025","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"10.1016\/j.xops.2026.101275_bib25","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41598-024-52315-w","article-title":"Choroidal remodeling following different anti-VEGF therapies in neovascular AMD","volume":"14","author":"Boscia","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.xops.2026.101275_bib26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamaophthalmol.2013.692","article-title":"Effect of intravitreous anti-vascular endothelial growth factor therapy on choroidal thickness in neovascular age-related macular degeneration using spectral-domain optical coherence tomography","volume":"131","author":"Branchini","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101275_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/j.1755-3768.2022.0631","article-title":"Choroidal thickness in exudative age-related macular degeneration and influence of intravitreal anti-VEGF treatment","volume":"100","author":"Rodrigues","year":"2022","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"10.1016\/j.xops.2026.101275_bib28","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1167\/iovs.09-4383","article-title":"Choroidal thickness in healthy Japanese subjects","volume":"51","author":"Ikuno","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.xops.2026.101275_bib29","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1007\/s10792-022-02292-8","article-title":"Correlation of choroidal thickness with age in healthy subjects: automatic detection and segmentation using a deep learning model","volume":"42","author":"Lin","year":"2022","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.xops.2026.101275_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144156","article-title":"Correlation of aging and segmental choroidal thickness measurement using swept source optical coherence tomography in healthy eyes","volume":"10","author":"Wakatsuki","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.xops.2026.101275_bib31","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.63.2.34","article-title":"Choroidal thickness and its Association with Age, axial length, and refractive error in Chinese adults","volume":"63","author":"Xie","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"13","key":"10.1016\/j.xops.2026.101275_bib32","doi-asserted-by":"crossref","first-page":"9555","DOI":"10.1167\/iovs.11-8076","article-title":"Choroidal thickness in healthy Chinese subjects","volume":"52","author":"Ding","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.xops.2026.101275_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000513048","article-title":"Brolucizumab: a newly developed Anti-VEGF molecule for the treatment of neovascular age-related macular degeneration","volume":"244","author":"Tadayoni","year":"2021","journal-title":"Ophthalmologica"},{"issue":"3","key":"10.1016\/j.xops.2026.101275_bib34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/IAE.0000000000003344","article-title":"Changes in systemic levels of vascular endothelial growth factor after intravitreal injection of Aflibercept or brolucizumab for neovascular age-related macular degeneration","volume":"42","author":"Angermann","year":"2022","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.xops.2026.101275_bib35","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/13543784.2019.1667333","article-title":"Tie-2\/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease","volume":"28","author":"Hussain","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.xops.2026.101275_bib36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.xops.2026.101275_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2021.102582","article-title":"Long-term effect of intravitreal aflibercept treatment on choroidal vascularity index in neovascular age-related macular degeneration","volume":"36","author":"Alis","year":"2021","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"2","key":"10.1016\/j.xops.2026.101275_bib38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.preteyeres.2009.12.002","article-title":"The multifunctional choroid","volume":"29","author":"Nickla","year":"2010","journal-title":"Prog Retin Eye Res"},{"issue":"8","key":"10.1016\/j.xops.2026.101275_bib39","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1001\/archopht.1996.01100140179011","article-title":"Localization of vascular endothelial growth factor in human retina and choroid","volume":"114","author":"Lutty","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2026.101275_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108201","article-title":"Stromal cells cultivated from the choroid of human eyes display a mesenchymal stromal cell (MSC) phenotype and inhibit the proliferation of choroidal vascular endothelial cells in vitro","volume":"200","author":"Alexander","year":"2020","journal-title":"Exp Eye Res"},{"issue":"3","key":"10.1016\/j.xops.2026.101275_bib41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/ICB.0000000000001405","article-title":"Successful treatment of severe peripapillary pachychoroid syndrome with anti-vascular endothelial growth factor therapy","volume":"18","author":"Abraham","year":"2024","journal-title":"Retin Cases Brief Rep"},{"issue":"6","key":"10.1016\/j.xops.2026.101275_bib42","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/bjophthalmol-2016-309281","article-title":"Choroidal thickness in non-neovascular versus neovascular age-related macular degeneration: a fellow eye comparative study","volume":"101","author":"Govetto","year":"2017","journal-title":"Br J Ophthalmol"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:11:19Z","timestamp":1786954279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526002137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666914526002137"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101275","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Choroidal Changes after Intravitreal Aflibercept, Faricimab, Brolucizumab, and High-Dose Aflibercept in Treatment-Na\u00efve Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101275"}}